EORTC elderly task force position paper: Approach to the older cancer patient

European Journal of Cancer

Volumn 46, Issue 9, 2010, Pages 1502-1513

  Pallis, A G ^a   Fortpied, C ^a   Wedding, U ^b   Van Nes, M C ^c   Penninckx, B ^a   Ring, A ^d   Lacombe, D ^a   Monfardini, S ^e   Scalliet, P ^f   Wildiers, H ^g  

^a EORTC DATA CENTER   (Belgium)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Department of Haematology Oncology and Palliative Care ^*  (Belgium)

^d ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^e IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Aged; Cancer in the older; Clinical trials; Elderly; EORTC; Geriatric oncology; Older; Position paper

Indexed keywords

RECOMBINANT COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

AGE; AGED; AGING; ANEMIA; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; FEBRILE NEUTROPENIA; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GERIATRIC CARE; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; KARNOFSKY PERFORMANCE STATUS; LIFE EXPECTANCY; MEDICAL DECISION MAKING; METHODOLOGY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SOCIAL STATUS; SOLID TUMOR; TREATMENT FAILURE; CLINICAL TRIAL (TOPIC); COMPLICATION; METABOLISM; NEOPLASMS;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; GERIATRIC ASSESSMENT; HUMANS; NEOPLASMS; PATIENT SELECTION; PROGNOSIS;

EID: 77952743404     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.022     Document Type: Article

References (111)

1. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80 7 (1997) 1273-1283
2. Wedding U., Bokemeyer C., and Meran J.G. Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG). Onkologie 27 1 (2004) 72-82
3. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 36 14 (2000) 1741-1754
4. Final Concept Paper E7 (R1): Studies in support of special populations: geriatrics (revision of the ICH E7 Guideline); 2009. .
5. European Medicines Agency. ICH Topic E7. Studies in support of special populations: geriatrics; 1994. .
6. Extermann M., Chen H., Cantor A.B., et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 38 11 (2002) 1466-1473
7. De Marinis M., Franceschi C., Monti D., et al. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 80 3 (2006) 219-227
8. Ershler W.B. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 41 2 (1993) 176-181
9. Reuben D.B., Cheh A.I., Harris T.B., et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 50 4 (2002) 638-644
10. Simm A., Nass N., Bartling B., et al. Potential biomarkers of ageing. Biol Chem 389 3 (2008) 257-265
11. Shawi M., and Autexier C. Telomerase, senescence and ageing. Mech Ageing Dev 129 1-2 (2008) 3-10
12. Aubert G., and Lansdorp P.M. Telomeres and aging. Physiol Rev 88 2 (2008) 557-579
13. Minamino T., and Komuro I. Role of telomeres in vascular senescence. Front Biosci 13 (2008) 2971-2979
14. De Meyer T., Rietzschel E.R., De Buyzere M.L., et al. Studying telomeres in a longitudinal population based study. Front Biosci 13 (2008) 2960-2970
15. Maccormick R.E. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty?. Med Hypotheses 67 2 (2006) 212-215
16. Kumar A., Soares H.P., Balducci L., et al. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 25 10 (2007) 1272-1276
17. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 27 (1999) 2061-2067
18. Lewis J.H., Kilgore M.L., Goldman D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 7 (2003) 1383-1389
19. Talarico L., Chen G., and Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 22 22 (2004) 4626-4631
20. Townsley C.A., Selby R., and Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23 13 (2005) 3112-3124
21. Townsley C.A., Chan K.K., Pond G.R., et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer (2006) 634-639
22. Basche M., Baron A., Eckhardt S.G., et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract 4 4 (2008) 162-168
23. Lancet J.E., Willman C.L., and Bennett J.M. Acute myelogenous leukemia and aging. Clinical interactions. Hematol Oncol Clin North Am 14 1 (2000) 251-267
24. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987-94.
25. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8 12 (2007) 1101-1115
26. Diab S.G., Elledge R.M., and Clark G.M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92 7 (2000) 550-556
27. Gennari R., Curigliano G., Rotmensz N., et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer 101 6 (2004) 1302-1310
28. Wildiers H., Van Calster B., van de Poll-Franse L.V., et al. Relationship between age and axillary lymph node involvement in women with breast cancer. J Clin Oncol 27 18 (2009) 2931-2937
29. Albain K.S., Crowley J.J., LeBlanc M., et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9 9 (1991) 1618-1626
30. Finkelstein D.M., Ettinger D.S., and Ruckdeschel J.C. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 4 5 (1986) 702-709
31. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65 1 (1980) 25-32
32. Mitry E., Douillard J.Y., Van C.E., et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15 7 (2004) 1013-1017
33. Figer A., Perez-Staub N., Carola E., et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110 12 (2007) 2666-2671
34. Extermann M., and Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25 14 (2007) 1824-1831
35. Carreca I., Balducci L., and Extermann M. Cancer in the older person. Cancer Treat Rev 31 5 (2005) 380-402
36. Stuck A.E., Siu A.L., Wieland G.D., et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342 8878 (1993) 1032-1036
37. Maas H.A., Janssen-Heijnen M.L., Olde Rikkert M.G., et al. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 43 15 (2007) 2161-2169
38. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 20 2 (2002) 494-502
39. McCorkle R., Strumpf N.E., Nuamah I.F., et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 48 12 (2000) 1707-1713
40. Goodwin J.S., Satish S., Anderson E.T., et al. Effect of nurse case management on the treatment of older women with breast cancer. J Am Geriatr Soc 51 9 (2003) 1252-1259
41. Christman K., Muss H.B., Case L.D., et al. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. [see comment]. JAMA 268 1 (1992) 57-62
42. Belani C.P., and Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 104 12 (2005) 2766-2774
43. Kohne C.H., Folprecht G., Goldberg R.M., et al. Chemotherapy in elderly patients with colorectal cancer. Oncologist 13 4 (2008) 390-402
44. Repetto L., Venturino A., Fratino L., et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 39 7 (2003) 870-880
45. Audisio R.A., Pope D., Ramesh H.S., et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 65 2 (2008) 156-163
46. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 3 (2005) 241-252
47. Saliba D., Elliott M., Rubenstein L.Z., et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49 12 (2001) 1691-1699
48. Slaets J.P. Vulnerability in the elderly: frailty. Med Clin North Am 90 4 (2006) 593-601
49. Soubeyran P., Bellera C.A., Gregoire F., et al. Validation of a screening test for elderly patients in oncology. J Clin Oncol 26 Suppl. 20 (2008) abstr 20568
50. Mohile S.G., Bylow K., Dale W., et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109 4 (2007) 802-810
51. Schuurmans H., Steverink N., Lindenberg S., et al. Old or frail: what tells us more?. J Gerontol A: Biol Sci Med Sci 59 9 (2004) M962-M965
52. Overcash J.A., Beckstead J., Extermann M., et al. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol 54 2 (2005) 129-136
53. Wildiers H., Highley M.S., de Bruijn E.A., et al. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42 14 (2003) 1213-1242
54. Brenner B.M., Meyer T.W., and Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307 11 (1982) 652-659
55. Lichtman S.M., Wildiers H., Launay-Vacher V., et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43 1 (2007) 14-34
56. Deppermann K.M. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 33 Suppl. 1 (2001) S115-S120
57. Crivellari D. Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group. Tumori 88 Suppl. 1 (2002) S81-S82
58. Dees E.C., O'Reilly S., Goodman S.N., et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18 6 (2000) 521-529
59. Lyman G.H., Dale D.C., and Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21 24 (2003) 4524-4531
60. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 3 (2002) 173-181
61. Rocha Lima C.M., Herndon J.E., Kosty M., et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 94 1 (2002) 181-187
62. Sonneveld P., de Ridder M., van der Lelie H., et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13 10 (1995) 2530-2539
63. Gomez H., Mas L., Casanova L., et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16 7 (1998) 2352-2358
64. Bastion Y., Blay J.Y., Divine M., et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival - a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 15 8 (1997) 2945-2953
65. Lyman G.H., Kuderer N.M., and Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112 5 (2002) 406-411
66. Repetto L., Biganzoli L., Koehne C.H., et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39 16 (2003) 2264-2272
67. Repetto L., Carreca I., Maraninchi D., et al. Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol 45 2 (2003) 123-128
68. NCCN Clinical Practice Guidelines in Oncology. Senior adult oncology, V.I.2009; 2009. .
69. Balducci L., and Lyman G.H. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 19 5 (2001) 1583-1585
70. Balducci L., Hardy C.L., and Lyman G.H. Hematopoietic growth factors in the older cancer patient. Curr Opin Hematol 8 3 (2001) 170-187
71. Tumer N., Scarpace P.J., and Lowenthal D.T. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol 32 (1992) 271-302
72. Wu W.C., Rathore S.S., Wang Y., et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345 17 (2001) 1230-1236
73. Rizzo J.D., Lichtin A.E., Woolf S.H., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20 19 (2002) 4083-4107
74. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43 2 (2007) 258-270
75. Bohlius J., Schmidlin K., Brillant C., et al. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev 3 (2009) CD007303
76. Bohlius J., Schmidlin K., Brillant C., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373 9674 (2009) 1532-1542
77. Baker S.D., and Grochow L.B. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 13 (1997) 169-183
78. Piccirillo J.F., Tierney R.M., Costas I., et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291 20 (2004) 2441-2447
79. Extermann M., Balducci L., and Lyman G.H. What threshold for adjuvant therapy in older breast cancer patients?. J Clin Oncol 18 8 (2000) 1709-1717
80. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 5 (1987) 373-383
81. Miller M.D., Paradis C.F., Houck P.R., et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatr Res 41 3 (1992) 237-248
82. Wedding U., Roehrig B., Klippstein A., et al. Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol 61 3 (2007) 269-276
83. Blower P., de Wit R., Goodin S., et al. Drug-drug interactions in oncology: why are they important and can they be minimized?. Crit Rev Oncol Hematol 55 2 (2005) 117-142
84. Sokol K.C., Knudsen J.F., and Li M.M. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 32 2 (2007) 169-175
85. Mitchell S.L., Teno J.M., Kiely D.K., et al. The clinical course of advanced dementia. N Engl J Med 361 16 (2009) 1529-1538
86. Wolfson C., Wolfson D.B., Asgharian M., et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344 15 (2001) 1111-1116
87. Seeman T.E., Berkman L.F., Kohout F., et al. Intercommunity variations in the association between social ties and mortality in the elderly. A comparative analysis of three communities. Ann Epidemiol 3 4 (1993) 325-335
88. Landi F., Zuccala G., Gambassi G., et al. Body mass index and mortality among older people living in the community. J Am Geriatr Soc 47 9 (1999) 1072-1076
89. de Vries S.H., Postma R., Raaijmakers R., et al. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol 51 2 (2007) 366-374
90. Satariano W.A., and Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120 2 (1994) 104-110
91. Piccirillo J.F., and Feinstein A.R. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 77 5 (1996) 834-842
92. Yancik R., Wesley M.N., Ries L.A., et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285 7 (2001) 885-892
93. Fleming T.R., Rothmann M.D., and Lu H.L. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 27 17 (2009) 2874-2880
94. Sanoff H.K., Bleiberg H., and Goldberg R.M. Managing older patients with colorectal cancer. J Clin Oncol 25 14 (2007) 1891-1897
95. Ardizzoni A., Favaretto A., Boni L., et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 23 3 (2005) 569-575
96. Nout R.A., Fiets W.E., Struikmans H., et al. The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer. Breast Cancer Res Treat 109 3 (2008) 567-572
97. Bottomley A., Vanvoorden V., Flechtner H., et al. The challenges and achievements involved in implementing Quality of Life research in cancer clinical trials. Eur J Cancer 39 3 (2003) 275-285
98. Yellen S.B., Cella D.F., and Leslie W.T. Age and clinical decision making in oncology patients. J Natl Cancer Inst 86 23 (1994) 1766-1770
99. Gelber R.D., Cole F.B., Gelber S., et al. Comparing treatments using quality-adjusted survival: the Q-twist method. Am Statist 49 2 (1995) 161-169
100. Reuben D.B., Rubenstein L.V., Hirsch S.H., et al. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 93 6 (1992) 663-669
101. Ansari R., Gonin R., Socinski M., et al. Eldelry subgroup analysis of a radnomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer. Proc Am Soc Clin Oncol 25 18S (2007) abstr 7665
102. Folprecht G., Seymour M.T., Saltz L., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26 9 (2008) 1443-1451
103. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 25 (2006) 4085-4091
104. Pignon T., Gregor A., Schaake K.C., et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 46 3 (1998) 239-248
105. European Medicines Agency. Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan, 2008; 2008/C 243/01.
106. Extermann M., and Muss H. Conducting clinical trials for patients who are frail or elderly. Proc Am Soc Clin Oncol Educational Book (2009) 289-293
107. Rodin M.B., and Mohile S.G. A practical approach to geriatric assessment in oncology. J Clin Oncol 25 14 (2007) 1936-1944
108. Launay-Vacher V., Chatelut E., Lichtman S.M., et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 18 8 (2007) 1314-1321
109. Lichtman S.M., Wildiers H., Chatelut E., et al. International Society of Geriatric Oncology Chemotherapy Taskforce. evaluation of chemotherapy in older patients - an analysis of the medical literature. J Clin Oncol 25 14 (2007) 1832-1843
110. Monfardini S., and Aapro M. Cancer treatment in the elderly: the need for a better organization. Ann Oncol 18 7 (2007) 1283-1284
111. Monfardini S., Aapro M.S., Bennett J.M., et al. Organization of the clinical activity of geriatric oncology: report of a SIOG (International Society of Geriatric Oncology) task force. Crit Rev Oncol Hematol 62 1 (2007) 62-73